{"organizations": [], "uuid": "7f8767e44e2efe2fc8f094705d50cc569fc7aaa6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://news.google.com/news?pz=1&cf=all&ned=de&hl=en&q=rnai&cf=all&output=rss", "section_title": "Google News: rnai", "url": "https://www.reuters.com/article/brief-alnylam-reports-preclinical-data-d/brief-alnylam-reports-preclinical-data-demonstrating-central-nervous-system-delivery-of-rnai-therapeutics-idUSFWN1SF0PM", "country": "US", "domain_rank": 408, "title": "BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics - Reuters", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-05-08T14:13:00.000+03:00", "replies_count": 0, "uuid": "7f8767e44e2efe2fc8f094705d50cc569fc7aaa6"}, "author": "", "url": "https://www.reuters.com/article/brief-alnylam-reports-preclinical-data-d/brief-alnylam-reports-preclinical-data-demonstrating-central-nervous-system-delivery-of-rnai-therapeutics-idUSFWN1SF0PM", "ord_in_thread": 0, "title": "BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics - Reuters", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "alnylam pharmaceuticals inc", "sentiment": "none"}, {"name": "rnai therapeutics reuters", "sentiment": "none"}, {"name": "alnylam", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8, 2018 / 11:10 AM / in 8 hours BRIEF-Alnylam Reports Preclinical Data Demonstrating Central Nervous System Delivery Of RNAi Therapeutics Reuters Staff\nMay 8 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM REPORTS PRECLINICAL DATA DEMONSTRATING CENTRAL NERVOUS SYSTEM (CNS) DELIVERY OF RNAI THERAPEUTICS\n* ALNYLAM PHARMACEUTICALS INC - COMPANY EXPECTS FIRST CNS-TARGETED DEVELOPMENT CANDIDATE IN 2018\n* ALNYLAM PHARMACEUTICALS - EXPECTS FIRST IND IN LATE 2019/EARLY 2020, AND CAPACITY FOR SUSTAINED PIPELINE OF ONE OR MORE CNS INDS PER YEAR THEREAFTER Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-08T14:13:00.000+03:00", "crawled": "2018-05-08T21:55:25.001+03:00", "highlightTitle": ""}